Boron-containing small molecules
Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.
1. A method of treating a condition or disease, in an animal, the method comprising administering to the animal a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, chlorine, bromine, iodine, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH;
R b is selected from the group consisting of OR 4 and NR 4 R 5 ,
wherein R 4 and R 5 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring;
wherein the condition or disease is selected from the group consisting of a helminth-associated disease, psoriasis, atopic dermatitis, rheumatoid arthritis, an inflammatory bowel disease, asthma, diabetes, obesity and chronic obstructive pulmonary disease,
thereby treating the condition or disease.
2. The method of claim 1 , wherein R c is chlorine or bromine or iodine.
3. The method of claim 1 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
4. The method of claim 1 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted cycloalkyl.
5. The method of claim 1 , wherein the compound, or pharmaceutically acceptable salt thereof, has a structure according to a formula which is selected from the group consisting of
wherein R c is chlorine.
6. The method of claim 1 , wherein the condition or disease is a helminth-associated disease which is schistosomiasis.
7. A method of decreasing the release of a cytokine or a chemokine, the method comprising: contacting a cell with the compound or a pharmaceutically acceptable salt thereof, having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, chlorine, bromine, iodine, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH;
R b is selected from the group consisting of OR 4 and NR 4 R 5 ,
wherein R 4 and R 5 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring;
thereby decreasing the release of the cytokine or chemokine by the cell.
8. A method of inhibiting a phosphodiesterase (PDE), the method comprising: contacting the phosphodiesterase with a compound or a pharmaceutically acceptable salt thereof, having a structure according to a formula which is selected from the group consisting of:
wherein
R d is selected from the group consisting of H, halogen, and unsubstituted alkyl;
R c is selected from the group consisting of cyano, chlorine, bromine, iodine, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted alkoxy;
X is N or CH;
R b is selected from the group consisting of OR 4 and NR 4 R 5 ,
wherein R 4 and R 5 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring;
thereby inhibiting the phosphodiesterase.
9. The method of claim 8 , wherein said phosphodiesterase is phosphodiesterase4 (PDE4).
10. The method of claim 7 , wherein R c is chlorine or bromine or iodine.
11. The method of claim 7 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
12. The method of claim 7 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted cycloalkyl.
13. The method of claim 7 , wherein the compound, or pharmaceutically acceptable salt thereof, has a structure according to a formula which is selected from the group consisting of
wherein R c is chlorine.
14. The method of claim 7 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(2-isopropoxyethoxy)nicotinonitrile.
15. The method of claim 7 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(4-oxopentyloxy)nicotinonitrile.
16. The method of claim 1 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(2-isopropoxyethoxy)nicotinonitrile.
17. The method of claim 1 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(4-oxopentyloxy)nicotinonitrile.
18. The method of claim 8 , wherein R c is chlorine or bromine or iodine.
19. The method of claim 8 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
20. The method of claim 8 , wherein R b is OR 4 , and R 4 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted cycloalkyl.
21. The method of claim 8 , wherein the compound, or pharmaceutically acceptable salt thereof, has a structure according to a formula which is selected from the group consisting of
wherein R c is chlorine.
22. The method of claim 8 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(2-isopropoxyethoxy)nicotinonitrile.
23. The method of claim 8 , wherein said compound is 5-chloro-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)-2-(4-oxopentyloxy)nicotinonitrile.